I-Mab's Strategic Reorientation: A New Era for Global Biotech Innovation and Investment Risks

---

The biotechnology sector is no stranger to reinvention, but I-Mab's (now rebranded as NovaBridge Biosciences) strategic transformation represents a bold redefinition of its role in the global innovation ecosystem. By pivoting to a dual-listing structure on NASDAQ and the Hong Kong Stock Exchange (HKEX), adopting a leaner operational model, and prioritizing high-impact clinical assets, the company is positioning itself to capitalize on the Asia-Pacific region's growing influence in biopharma. However, this reorientation also introduces risks that investors must carefully evaluate.

Strategic Transformation: A Global Platform with Focused Ambitions

I-Mab's decision to rebrand as NovaBridge Biosciences, according to a GlobeNewswire release, underscores its ambition to become a bridge between Asia's innovation pipeline and global markets. The company's new business model emphasizes business development and translational clinical development, aiming to accelerate access to therapies like givastomig-a Claudin 18.2 x 4-1BB bispecific antibody in Phase 1b trials for gastric cancer, the release reported. With an 83% objective response rate observed in early trials, according to the same release, givastomig has emerged as a cornerstone asset, supported by a planned global Phase 2 trial in Q1 2026.

The acquisition of VIS-101, a bifunctional biologic targeting VEGF-A and ANG2 for ophthalmic diseases, further diversifies the pipeline, the release added. This move, facilitated by a newly established subsidiary, Visara, Inc., highlights NovaBridge's commitment to expanding into high-growth therapeutic areas. Such strategic acquisitions align with broader trends: the release noted that Asia-Pacific-originated biopharma assets now account for over 30% of global developments, driven by faster clinical trial enrollment and cost efficiencies.

Financial Resilience and Capital Allocation

NovaBridge's financial restructuring has been pivotal to its transformation. As of June 30, 2025, the company held $165.6 million in cash and short-term investments, the release reported, bolstered by a recent $61.2 million capital raise in August 2025. This pro-forma balance sheet of $226.8 million is projected to fund operations through Q4 2028, providing a buffer for its Phase 2 trials and potential collaborations.

The company's leaner operating model-shifted to U.S.-based leadership and streamlined operations-has already reduced net losses compared to prior years, as noted in a Needham conference presentation. Additionally, extinguishing redemption obligations and securing upstream rights to Claudin 18.2 through the Bridge Health acquisition have minimized future liabilities. These measures suggest a disciplined approach to capital preservation, critical for a clinical-stage biotech navigating high R&D costs.

Market Implications and Long-Term Value Drivers

NovaBridge's dual-listing strategy on NASDAQ and HKEX is not merely a financial maneuver but a signal of intent to tap into Asia's $80 billion biopharma collaboration market, the release asserted. By leveraging Hong Kong's capital markets and NASDAQ's liquidity, the company aims to attract a broader investor base, including those seeking exposure to Asia's innovation-driven biotech sector.

The Asia-Pacific region's role as a biopharma innovation hub cannot be overstated. With over 30% of global assets under development originating here, NovaBridge's focus on regional strengths-such as rapid trial enrollment and lower operational costs-positions it to outpace peers in traditional markets. However, this strategy hinges on the successful execution of its pipeline, particularly givastomig, which faces stiff competition in the oncology space.

Risks and Challenges

While NovaBridge's repositioning is compelling, several risks warrant scrutiny. First, clinical trial outcomes for givastomig and other assets are binary events. A failure in Phase 2 trials could erode investor confidence and deplete cash reserves before the projected 2028 runway. Second, the company's reliance on a narrow pipeline increases vulnerability to regulatory delays or competitive pressures. Third, the dual-listing strategy introduces complexities in cross-border compliance and investor expectations, particularly in Hong Kong's more risk-averse market.

Moreover, the ophthalmic segment-while promising-faces an established standard of care. VIS-101's differentiation must be clinically and commercially validated to justify its $37 million investment, the release cautioned.

Conclusion: Balancing Optimism and Caution

NovaBridge Biosciences' strategic shift reflects a calculated bet on the future of global biotech. By aligning with Asia-Pacific trends, optimizing capital structure, and focusing on high-impact assets, the company has laid a foundation for long-term value creation. However, the path ahead remains fraught with uncertainties. Investors must weigh the potential of givastomig and VIS-101 against the inherent risks of clinical development and market execution. For those with a long-term horizon and tolerance for volatility, NovaBridge's transformation offers an intriguing opportunity-but one that demands continuous scrutiny.

---